RPL554: Ph IIa started

Verona began a double-blind, placebo-controlled, 3-way crossover, U.K. Phase IIa trial to evaluate 1.5 and 6 mg inhaled RPL554 once daily plus 10 µg Spiriva tiotropium once daily in about 30 patients....